<DOC>
	<DOCNO>NCT01588405</DOCNO>
	<brief_summary>This multi-center , open-label study assess tolerability safety transition subject stable Pulmonary Arterial Hypertension ( PAH ) continuous intravenous ( IV ) subcutaneous ( SC ) Remodulin infusion oral treprostinil ( UT-15C sustain release ( SR ) tablet ) . This study consist in-hospital transition phase , dose optimization/evaluation phase , follow phase .</brief_summary>
	<brief_title>RemodulinÂ® Oral Treprostinil Transition</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Between 15 80 year age , inclusive , weigh least 40 kg diagnosis PAH Have stable disease confirm recent right heart catheterization Baseline 6MWD least 250 meter Have receive Remodulin least 90 day stable dose least 30 day prior Baseline visit ; dose Remodulin must 2575 ng/kg/min , inclusive Must also receive endothelin receptor antagonist ( ERA ) and/or phosphodiesterase5 inhibitor ( PDE5i ) least 90 day stable dose least 30 day prior Baseline WHO functional class III IV subject exclude</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>UT-15C SR</keyword>
	<keyword>PAH</keyword>
</DOC>